Imbruvica (Ibrutinib)

: Imbruvica is a Bruton’s tyrosine kinase (BTK) inhibitor used in the treatment of various B-cell cancers, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Its ability to target cancer cells while sparing most normal cells has made it a breakthrough therapy in oncology. Imbruvica’s success in improving patient outcomes in difficult-to-treat cancers has solidified its place as a top-selling drug.